

Ref: NLL\CS\2011-

Dated: 08.12.2011

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub. Investors Information Release


Dear Sirs,

Please find attached herewith an Investor Information release that ***"European cGMP Approval for NecLife's Cephalosporin Formulation Facility"***.

This is for your information and necessary dissemination to investors.

Thanking you,

Yours faithfully,
For Nectar Lifesciences Limited



(Dinesh Dua)
CEO & Director



NECTAR LIFESCIENCES LIMITED

Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

European cGMP Approval for NecLife's Cephalosporin Formulation Facility

Chandigarh, 8 December, 2011

Nectar Lifesciences Limited (NecLife), a fast growing manufacturer of generic active pharmaceutical ingredients (APIs) and Formulation products has achieved yet another significant milestone by receiving European cGMP ("Current Good Manufacturing Practices") approval for its Cephalosporin Formulations manufacturing facility in Baddi, Himachal Pradesh. This approval will facilitate NecLife's entry into lucrative 27 European Union member states, EEU, South Africa and Middle East markets on account of mutual recognition.

After receiving EU cGMP for API facility in October 2011, NecLife has received the European cGMP compliance certification for its Cephalosporin Formulations facility in Baddi for Injectables Cephalosporins. This approval has been received following the successful inspection by the Hungarian Authority - National Institute for Quality and Organizational Development in Healthcare and Medicines, National Institute of Pharmacy (GYEMSZI-OGYI) in June 2011. Hungary being a member of European Union, the GYEMSZI-OGYI Certificate is accepted by all EU Health Authorities and by authorities of several other countries.

NecLife's Formulations facility, Unit-VI, has received this approval for Cefotaxime sodium for injection, Ceftriaxone sodium for injection and Cefuroxime sodium for injection. Together these 3 products have a market potential in excess of US\$ 1 Billion in the European countries.

Till date, NecLife has filed 27 Drug Master Files (DMFs) and 6 Abbreviated New Drug Applications (ANDAs). NecLife has very ambitious plan of filing over 20 DMFs and multiple ANDAs/EU dossiers in US and EU markets in year 2012. These filings by NecLife will result in robust topline as well as bottomline for the company from year 2013 onwards in view of gestation period for regulatory approvals which take significant time in view of the current pendency.

About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and Carbapenem active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 3 oral molecules and global No. 2 position in 2 sterile molecules. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, Carbapenem and other APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 507 9049

Email: dinesh.dua@neclife.com


08/12/2011


Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.